| | Mosby's Drug Consult Top 200 |
 | | In a study comparing chronic dosing with Wellbutrin SR tablets 150 mg twice daily to the immediate-release formulation of bupropion at 100 mg three times daily, peak plasma concentrations of bupropion at steady-state for Wellbutrin SR tablets were approximately 85% of those achieved with theimmediate-release formulation. |
 | | As both Wellbutrin XL and the sustained-release formulation of bupropion (Wellbutrin SR) are bioequivalent to the immediate-release formulation of bupropion, the seizure incidence with Wellbutrin XL, while not formally evaluated in clinical trials, may be similar to that presented for the immediate-release and sustained-release formulations of bupropion. |
 | | Wellbutrin SR should be used with caution in patients with hepatic impairment (including mild to moderate hepatic cirrhosis)and a reduced frequency and/or dose should be considered in patients with mild to moderate hepatic cirrhosis (see CLINICAL PHARMACOLOGY, WARNINGS, and PRECAUTIONS). |
| www.mosbysdrugconsult.com /DrugConsult/Top_200/Drugs/e0550.html (13349 words) |